Special Issue "Lipid Biomarkers in Alzheimer's Disease"
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".
Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 7200
Special Issue Editor

Interests: clinical biomarkers; proteomics; metabolomics; lipidomics; diagnosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The number of patients with dementia is increasing as the population ages in many countries. Dementia can be subdivided into several categories and Alzheimer's disease (AD) accounts for about 70% of dementia patients. Although AD research is being conducted vigorously all over the world, the pathogenesis of AD is still largely unknown and the lack of a fundamental cure or appropriate early diagnosis places AD among the diseases with the highest unmet needs. Apolipoprotein E4 (APOE4) is known to be a strong risk factor for the development of AD. APOE is a member of the family of lipid-binding proteins, which are involved in lipid metabolism and a major transporter of cholesterol in the brain. Several studies have also shown that polyunsaturated fatty acid (PUFA) intake reduces the risk of Alzheimer's disease. Aspirin, which inhibits cyclooxygenase, an enzyme involved in the metabolism of arachidonic acid has long been claimed to be effective in preventing AD. It is also said that the effect of aspirin on AD is mediated by proliferator-activated receptor alpha (PPAR alpha), a receptor activated by free fatty acids. Furthermore, amyloid protein has been the main focus of AD research, and its precursor, amyloid precursor protein (APP), is a membrane protein. Lipids are the major components of membranes. Thus, there is a high possibility that lipids are related to AD. Therefore, we have planned a Special Issue on Lipid Biomarkers in Alzheimer's disease.
Prof. Dr. Yoshiya Oda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Lipid biomarkers for Alzheimer’s disease
- Lipid metabolism in Alzheimer’s disease
- Lipidomics for Alzheimer’s disease
- Biomarker technology platforms
- Dietary lipids and Alzheimer’s disease prevention